Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other, SGLT2i Sep 16 | 2020Apple Cites T1DM Omnipod Patient Story at Tuesday Event; Jardiance Post-MI Trial (EMPACT-MI) Receives FDA FTD; Adocia Topline Results from M1Pram Ph1b Trial Extension; Welldoc/UMD Employs AI to Identify Digital Health Habits; Oramed’s Positive Diabetes Market Survey Results; Diamyd Receives $13.9M Towards Companion Medical SharesPurchase Blast
$599
Posted in: Glucose Monitoring Sep 15 | 2020Senseonics Hosts Investor Event with Special Guest AscensiaPurchase Blast
$599
Posted in: Glucose Monitoring, Other Sep 14 | 2020Diamyd's Ph2b DIAGNODE-2 Trial Topline Results; New MicroTech Medical BGM 510(k) Clearance; Voluntis Announces €2M in FundingPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, SGLT2i Sep 14 | 2020High-dose Trulicity, DAPA-HF and Gvoke up for Opinions; CHMP Agenda September 14-17Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Sep 11 | 2020Thoughts on Newly Permanent Lilly Insulin+Baqsimi Copay Cards; New Novo+ACC ASCVD Registry; ProSciento Receives VC InvestmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Sep 10 | 2020New Tirzepatide + Glargine U100 vs. Basal-Bolus Trial (SURPASS-6)Purchase Blast
$599
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Sep 08 | 2020Thoughts on Autolus's CAR-T Program; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Glucagon, Other Sep 04 | 2020Danilo Verge and David Kendall Join ZealandPurchase Blast
$599
Posted in: Autologous, CAR-T, CD19 Sep 04 | 2020Gilead Highlights No Impact of COVID-19 on Yescarta Sales; Two New LCM Initiatives for Yescarta; Q2 2020 Earnings Call SummaryPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T Sep 03 | 2020bluebird bio Highlights Ide-cel Resubmission; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Other Sep 02 | 2020Former Head of BI Diabetes/CardioMetabolism Joins NovoPurchase Blast
$599
Posted in: Glucose Monitoring Sep 01 | 2020Libre 2 Available for Medicare Patients; Senseonics Receives Positive Medicare Local Coverage DeterminationsPurchase Blast
$599
Posted in: SGLT2i Sep 01 | 2020AZ Provides Additional DAPA-CKD Commentary During Post-Results Investor CallPurchase Blast
$599
Posted in: BCMA, CAR-T, CD19 Sep 01 | 2020Thoughts on Allogene’s AlloCAR Program; Q2 2020 Earnings Call SummaryPurchase Blast
$599
Posted in: BCMA, CAR-T, CD19 Sep 01 | 2020BMS Highlights Ide-cel FDA Re-submission; Q2 2020 Earnings CallPurchase Blast
$599
Posted in: Insulin Delivery Aug 31 | 2020Medtronic's 770G Pump Approved in Peds Down to 2 Years of AgePurchase Blast
$599
Posted in: GLP-1RA Aug 31 | 2020New Oral Sema High-Dose and Flexible Administration Ph1 Trials from NovoPurchase Blast
$599
Posted in: Basal Insulin Aug 31 | 2020Biocon/Mylan Launch Semglee in US at 65% WAC Discount to LantusPurchase Blast